Thus, our study might expand the clinical implication of the pharmacological inhibition of PIN1 by ATRA in the treatment of cancers with wild-type VHL. Although our study is mainly focused in TNBC, further investigation need warranted especially in pancreatic cancer and other lethal cancers with worse prognosis and no targeted therapies. This evidence concerns the gene VHL and familial pancreatic carcinoma.